Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only

Oncology Reports

Volumn 21, Issue 2, 2009, Pages 507-513

  De Schutter, H ^a   Geeraerts, H ^a   Verbeken, E ^a   Nuyts, Sandra ^a  

^a United Arab Emirates   (Belgium)

Author keywords

CDH1; Head and neck squamous cell carcinoma; Promoter hypermethylation; Radiotherapy; TIMP3

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UVOMORULIN; APOPTOSIS REGULATORY PROTEIN; CADHERIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CDH1 PROTEIN, HUMAN; DEATH-ASSOCIATED PROTEIN KINASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RASSF1 PROTEIN, HUMAN; TIMP3 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE SILENCING; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RADIATION DOSE FRACTIONATION; TREATMENT RESPONSE; TUMOR BIOPSY; DISEASE FREE SURVIVAL; GENETICS; HEAD AND NECK TUMOR; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; CADHERINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENE SILENCING; GENES, P16; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 62849127213     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000251     Document Type: Article

References (44)

1. Bourhis J, Fortin A, Dupuis O, Domenge C, Lusinchi A, Marandas P, Schwaab G, Armand JP, Luboinski B and Malaise E: Very accelerated radiation therapy: preliminary results in locally unresectable head and neck carcinomas. Int J Radiat Oncol Biol Phys 32: 747-752, 1995.
2. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS and Ang KK: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48: 7-16, 2000.
3. Horiot JC, Le Fur R, N'Guyen T, Chenal C, Schraub S, Alfonsi S, Gardani G, Van Den Bogaert W, Danczak S and Bolla M: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25: 231-241, 1992.
4. Horiot JC, Bontemps P, Van Den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, Bernier J, Lusinchi A, Stuschke M, Lopez-Torrecilla J, Begg AC, Pierart M and Collette L: Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44: 111-121, 1997.
5. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L and Evensen JF: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362: 933-940, 2003.
6. Pinto LH, Canary PC, Araujo CM, Bacelar SC and Souhami L: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21: 557-562, 1991.
7. Poulsen MG, Denham JW, Peters LJ, Lamb DS, Spry NA, Hindley A, Krawitz H, Hamilton C, Keller J, Tripcony L and Walker Q: A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiother Oncol 60: 113-122, 2001.
8. Kaanders JH, van der Kogel AJ and Ang KK: Altered fractionation: limited by mucosal reactions? Radiother Oncol 50: 247-260, 1999.
9. Khalil AA, Bentzen SM, Bernier J, Saunders MI, Horiot JC, Van Den Bogaert W, Cummings BJ and Dische S: Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. Int J Radiat Oncol Biol Phys 55: 568-575, 2003.
10. Van der Schueren E, Van Den Bogaert W, Vanuytsel L and Van Limbergen E: Radiotherapy by multiple fractions per day (MFD) in head and neck cancer: acute reactions of skin and mucosa. Int J Radiat Oncol Biol Phys 19: 301-311, 1990.
11. Nuyts S, Dirix P, Hermans R, Vander Poorten V, Delaere P, Weltens C and Van Den Bogaert W: Early experience with a hybrid accelerated radiotherapy schedule for locally advanced head and neck cancer. Head Neck 29: 720-730, 2007.
12. Esteller M: Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16 (Spec No. 1): R50-R59, 2007.
13. Gronbaek K, Hother C and Jones PA: Epigenetic changes in cancer. APMIS 115: 1039-1059, 2007.
14. Shaw RJ, Hall GL, Lowe D, Bowers NL, Liloglou T, Field JK, Woolgar JA and Risk JM: CpG island methylation phenotype (CIMP) in oral cancer: associated with a marked inflammatory response and less aggressive tumour biology. Oral Oncol 43: 878-886, 2007.
15. Kato K, Hara A, Kuno T, Mori H, Yamashita T, Toida M and Shibata T: Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res Clin Oncol 132: 735-743, 2006.
16. Righini CA, de Fraipont F, Timsit JF, Faure C, Brambilla E, Reyt E and Favrot MC: Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res 13: 1179-1185, 2007.
17. Dikshit RP, Gillio-Tos A, Brennan P, De Marco L, Fiano V, Martinez-Penuela JM, Boffetta P and Merletti F: Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers. Cancer 110: 1745-1751, 2007.
18. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M and Kelsey KT: Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21: 4231-4236, 2002.
19. de Moraes RV, Oliveira DT, Landman G, de Carvalho F, Caballero O, Nonogaki S, Nishimoto I and Kowalski LP: Ecadherin abnormalities resulting from CPG methylation promoter in metastatic and nonmetastatic oral cancer. Head Neck 30: 85-92, 2008.
20. Zuo C, Ai L, Ratliff P, Suen JY, Hanna E, Brent TP and Fan CY: O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 13: 967-975, 2004.
21. Ai L, Vo QN, Zuo C, Li L, Ling W, Suen JY, Hanna E, Brown KD and Fan CY: Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomarkers Prev 13: 150-156, 2004.
22. Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI and Sidransky D: Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res 9: 3635-3640, 2003.
23. Ha PK and Califano JA: Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 7: 77-82, 2006.
24. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG and Sidransky D: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60: 892-895, 2000.
25. Wong TS, Man MW, Lam AK, Wei WI, Kwong YL and Yuen AP: The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur J Cancer 39: 1881-1887, 2003.
26. Rosas SL, Koch W, Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J and Sidransky D: Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 61: 939-942, 2001.
27. Ruesga MT, Acha-Sagredo A, Rodriguez MJ, Aguirregaviria JI, Videgain J, Rodriguez C, de Pancorbo ML and Aguirre JM: p16(INK4a) promoter hypermethylation in oral scrapings of oral squamous cell carcinoma risk patients. Cancer Lett 250: 140-145, 2007.
28. Chang HW, Chow V, Lam KY, Wei WI and Yuen A: Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 94: 386-392, 2002.
29. Puri SK, Si L, Fan CY and Hanna E: Aberrant promoter hypermethylation of multiple genes in head and neck squamous cell carcinoma. Am J Otolaryngol 26: 12-17, 2005.
30. Marsit CJ, Houseman EA, Christensen BC, Eddy K, Bueno R, Sugarbaker DJ, Nelson HH, Karagas MR and Kelsey KT: Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 66: 10621-10629, 2006.
31. Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, Lotan R and El-Naggar AK: Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res 10: 3825-3830, 2004.
32. Viswanathan M, Tsuchida N and Shanmugam G: Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int J Cancer 105: 41-46, 2003.
33. Nayak CS, Carvalho AL, Jeronimo C, Henrique R, Kim MM, Hoque MO, Chang S, Jiang WW, Koch W, Westra W, Sidransky D and Califano J: Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma. Laryngoscope 117: 1376-1380, 2007.
34. Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, Field JK and Risk JM: Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer 94: 561-568, 2006.
35. Nakayama S, Sasaki A, Mese H, Alcalde RE, Tsuji T and Matsumura T: The E-cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas. Int J Cancer 93: 667-673, 2001.
36. Ogi K, Toyota M, Ohe-Toyota M, Tanaka N, Noguchi M, Sonoda T, Kohama G and Tokino T: Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 8: 3164-3171, 2002.
37. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM, Moots PP, Lechner JF, Stidley CA and Crowell RE: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62: 2370-2377, 2002.
38. von Zeidler SV, Miracca EC, Nagai MA and Birman EG: Hypermethylation of the p16 gene in normal oral mucosa of smokers. Int J Mol Med 14: 807-811, 2004.
39. Fraga MF, Agrelo R and Esteller M: Cross-talk between aging and cancer: the epigenetic language. Ann NY Acad Sci 1100: 60-74, 2007.
40. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI, Huland H, Jones PA and Liang G: Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 41: 2769-2778, 2005.
41. Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR and Wu X: Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 12: 7329-7338, 2006.
42. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF and Minna JD: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61: 249-255, 2001.
43. Hodivala KJ and Watt FM: Evidence that cadherins play a role in the downregulation of integrin expression that occurs during keratinocyte terminal differentiation. J Cell Biol 124: 589-600, 1994.
44. Eriksen JG, Steiniche T and Overgaard J: The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma. Acta Oncol 44: 50-58, 2005.